TrialPanorama/TrialPanorama-database huggingface dataset:
Study: 37955741

Group type: EXPERIMENTAL
Intervention: Fedratinib 400 mg orally as intact capsules with a nutritional supplement
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Fedratinib contents dispersed in a nutritional supplement via nasogastric tube
Number of subjects: 58

Group type: EXPERIMENTAL
Intervention: Divided dose of 200 mg orally twice daily as intact capsules with a nutritional supplement
Number of subjects: 58
Study: 37955745

Group type: EXPERIMENTAL
Intervention: Postnatal steroids (betamethasone, hydrocortisone hemisuccinate)
Number of subjects: 192

Group type: COMPARATOR
Intervention: No postnatal steroids (control group)
Number of subjects: 192
Study: 37955825

Group type: COMPARATOR
Intervention: Sotrovimab 500 mg IV infusion
Number of subjects: 0

Group type: COMPARATOR
Intervention: Sotrovimab 500 mg IM dose
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37955849

Group type: EXPERIMENTAL
Intervention: Hybrid closed-loop (HCL) insulin delivery system
Number of subjects: 65
Study: 37955923

Group type: EXPERIMENTAL
Intervention: Palliative care education for community neurologists and team-based palliative care support via telehealth
Number of subjects: 359
Study: 37955951

Group type: EXPERIMENTAL
Intervention: TCT+PRIME
Number of subjects: 100

Group type: COMPARATOR
Intervention: CG+PRIME
Number of subjects: 100

Group type: EXPERIMENTAL
Intervention: PRIME app satisfaction
Number of subjects: 100
Study: 37955955

Group type: EXPERIMENTAL
Intervention: National Diabetes Prevention Program (DPP) delivered via telehealth modalities
Number of subjects: 1010
Study: 37955957

Group type: EXPERIMENTAL
Intervention: Facilitated WhatsApp group intervention (Vijana-SMART) for 6 months
Number of subjects: 55
Study: 37956087

Group type: EXPERIMENTAL
Intervention: Online self-management and recovery programs (1-2 lessons per week, 7-8 total lessons, 20-30 min per lesson)
Number of subjects: 435
Study: 37956111

Group type: EXPERIMENTAL
Intervention: MAISHA intervention in CRT01 (delivered to women in microfinance groups)
Number of subjects: 2044

Group type: EXPERIMENTAL
Intervention: MAISHA intervention in CRT02 (delivered to women not receiving microfinance)
Number of subjects: 2044

Group type: COMPARATOR
Intervention: Control group in CRT01 (not specified)
Number of subjects: 2044

Group type: COMPARATOR
Intervention: Control group in CRT02 (not specified)
Number of subjects: 2044
Study: 37956119

Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (IER) for 16 weeks (8x2 weeks of energy restriction interspersed with 7x1 week in energy balance)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Continuous energy restriction (CER) for 16 weeks
Number of subjects: 74

Group type: EXPERIMENTAL
Intervention: Intermittent energy restriction (IER)
Number of subjects: 74

Group type: COMPARATOR
Intervention: Continuous energy restriction (CER)
Number of subjects: 74
Study: 37956177

Group type: EXPERIMENTAL
Intervention: WeChat-based mini-app for PrEP promotion
Number of subjects: 70

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 70
Study: 37956238

Group type: EXPERIMENTAL
Intervention: Thromboprophylaxis (pharmacological and/or mechanical)
Number of subjects: 200
Study: 37956524

Group type: EXPERIMENTAL
Intervention: Evidence-based and structured skincare and prevention programme for six months
Number of subjects: 314

Group type: COMPARATOR
Intervention: Standard care as usual
Number of subjects: 314
Study: 37956679

Group type: EXPERIMENTAL
Intervention: dupilumab (100 mg for those weighing ≤30 kg and 200 mg for those weighing more than 30 kg, administered once every 2 weeks by subcutaneous injection)
Number of subjects: 365

Group type: COMPARATOR
Intervention: placebo (during VOYAGE) followed by dupilumab (100 or 200 mg, according to bodyweight, administered once every 2 weeks by subcutaneous injection)
Number of subjects: 365
Study: 37956738

Group type: EXPERIMENTAL
Intervention: Pemigatinib 13.5 mg once daily continuously (CD)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Pemigatinib 13.5 mg once daily intermittently (ID)
Number of subjects: 260

Group type: EXPERIMENTAL
Intervention: Pemigatinib
Number of subjects: 260
Study: 37956759

Group type: EXPERIMENTAL
Intervention: Older adults with cardiogenic shock (CS)
Number of subjects: 236
Study: 37956792

Group type: EXPERIMENTAL
Intervention: Medication adherence enhanced chronic disease care clinical decision support (eCDC-CDS) integrated within the electronic health record (EHR)
Number of subjects: 28

Group type: COMPARATOR
Intervention: Usual care (non-enhanced CDC-CDS)
Number of subjects: 28
Study: 37956897

Group type: EXPERIMENTAL
Intervention: Apixaban (5 mg twice daily)
Number of subjects: 40

Group type: COMPARATOR
Intervention: Warfarin (managed at INR goal of 2.0-2.5)
Number of subjects: 40
Study: 37956906

Group type: EXPERIMENTAL
Intervention: Oral probiotic formula containing Bifidobacterium bifidum, B lactis, Lactobacillus acidophilus, L paracasei, L rhamnosus, and Streptococcus thermophilus, 2 capsules daily for 2 weeks
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo, 2 capsules daily for 2 weeks
Number of subjects: 85

Group type: EXPERIMENTAL
Intervention: Oral probiotic formula
Number of subjects: 85

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 85
Study: 37956934

Group type: EXPERIMENTAL
Intervention: High-flow nasal cannula (HFNC)
Number of subjects: 330

Group type: COMPARATOR
Intervention: Conventional oxygen treatment (COT)
Number of subjects: 330
Study: 37956984

Group type: EXPERIMENTAL
Intervention: Tablet-based intervention designed to improve decision-making with respect to health risk behaviors
Number of subjects: 511

Group type: COMPARATOR
Intervention: Original data
Number of subjects: 511

Group type: EXPERIMENTAL
Intervention: Augmented data
Number of subjects: 511
Study: 37957132

Group type: EXPERIMENTAL
Intervention: Capecitabine-based chemotherapy regimens
Number of subjects: 2147

Group type: EXPERIMENTAL
Intervention: Nomogram for predicting severe toxicity
Number of subjects: 2147
Study: 37957175

Group type: EXPERIMENTAL
Intervention: Risk-directed therapy based on genetics and MRD
Number of subjects: 0
Study: 37957373

Group type: COMPARATOR
Intervention: KT-474 (SAR444656) administered as a single dose and then daily for 14 days in healthy volunteers (105 total).
Number of subjects: 126

Group type: EXPERIMENTAL
Intervention: KT-474 (SAR444656) administered for 28 days in an open-label cohort of 21 patients.
Number of subjects: 126
Study: 37957378

Group type: EXPERIMENTAL
Intervention: Neoadjuvant immune checkpoint blockade (ICB) treatment
Number of subjects: 88
Study: 37957412

Group type: EXPERIMENTAL
Intervention: Community-based peer support intervention
Number of subjects: 183

Group type: COMPARATOR
Intervention: Control (no intervention)
Number of subjects: 183
Study: 37957535

Group type: EXPERIMENTAL
Intervention: Mopati intervention (treatment partner intervention)
Number of subjects: 60

Group type: COMPARATOR
Intervention: Control group (standard care without Mopati)
Number of subjects: 60
Study: 37957586

Group type: EXPERIMENTAL
Intervention: Palovarotene (flare-up treatment regimen with higher dose for 2/4 weeks, followed by lower dose for 4/≥8 weeks; with or without chronic daily treatment)
Number of subjects: 172

Group type: COMPARATOR
Intervention: Palovarotene (in phase II trial)
Number of subjects: 172
Study: 37957689

Group type: EXPERIMENTAL
Intervention: HPV-DNA testing coupled with thermal ablation treatment
Number of subjects: 2227
Study: 37957702

Group type: EXPERIMENTAL
Intervention: Praziquantel and Vitamin A on Day 0, followed by SMC drugs on Days 1-3 (treatment group 1)
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Albendazole and praziquantel on Day 0, followed by SMC drugs on Days 1-3 (treatment group 2)
Number of subjects: 627

Group type: COMPARATOR
Intervention: SMC drugs only (control group)
Number of subjects: 627

Group type: EXPERIMENTAL
Intervention: Praziquantel and SMC drugs
Number of subjects: 627
Study: 37957757

Group type: EXPERIMENTAL
Intervention: Computer-based brief alcohol intervention (BAI)
Number of subjects: 961

Group type: EXPERIMENTAL
Intervention: In-person brief alcohol intervention (BAI)
Number of subjects: 961

Group type: COMPARATOR
Intervention: Assessment only (control group)
Number of subjects: 961
Study: 37957760

Group type: EXPERIMENTAL
Intervention: Grafting the jumping gap with 1:1 autogenous and xenograft particulates
Number of subjects: 24

Group type: COMPARATOR
Intervention: No grafting of the jumping gap
Number of subjects: 24
Study: 37957783

Group type: EXPERIMENTAL
Intervention: Multi-level program for reducing cardiometabolic disease risk factors
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Individual-level intervention
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Environment-level content adaptations
Number of subjects: 0
Study: 37957879

Group type: EXPERIMENTAL
Intervention: Micra
Number of subjects: 51

Group type: COMPARATOR
Intervention: Conventional PM
Number of subjects: 51
Study: 37958331

Group type: EXPERIMENTAL
Intervention: 25 mg lenalidomide maintenance therapy
Number of subjects: 0

Group type: COMPARATOR
Intervention: 5 mg lenalidomide maintenance therapy
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Both treatment arms
Number of subjects: 0
Study: 37958791

Group type: EXPERIMENTAL
Intervention: C7R-EBVSTs
Number of subjects: 0

Group type: COMPARATOR
Intervention: Unmodified EBVSTs
Number of subjects: 0
Study: 37960236

Group type: COMPARATOR
Intervention: SBRT alone (arm A)
Number of subjects: 88

Group type: EXPERIMENTAL
Intervention: SBRT + 6 months of ADT (arm B)
Number of subjects: 88
Study: 37960239

Group type: EXPERIMENTAL
Intervention: Kava
Number of subjects: 0
Study: 37960292

Group type: EXPERIMENTAL
Intervention: Miraculin-based food supplement
Number of subjects: 0

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 0
Study: 37960913

Group type: EXPERIMENTAL
Intervention: Wu Qin Xi group (WQX)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: Strength exercise mixed with endurance exercise training group (SE)
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: WQXSE hybrid exercise group
Number of subjects: 181

Group type: EXPERIMENTAL
Intervention: All groups
Number of subjects: 181
Study: 37960969

Group type: EXPERIMENTAL
Intervention: Teclistamab 1.5 mg/kg weekly after a step-up dosing schedule (0.06 mg/kg and 0.3 mg/kg, each separated by 2-4 days)
Number of subjects: 165

Group type: EXPERIMENTAL
Intervention: Teclistamab
Number of subjects: 165
Study: 37960985

Group type: EXPERIMENTAL
Intervention: Sapanisertib (3 mg orally daily for 21 days every 28 days)
Number of subjects: 16
Study: 37961215

Group type: EXPERIMENTAL
Intervention: IL13BBζ-CAR T cells delivered weekly into the lateral cerebral ventricles
Number of subjects: 6
Study: 37961426

Group type: EXPERIMENTAL
Intervention: Adapted TranS-C
Number of subjects: 10

Group type: COMPARATOR
Intervention: Standard TranS-C
Number of subjects: 10
Study: 37961433

Group type: EXPERIMENTAL
Intervention: High frequency (HF) rTMS to the left dorsolateral prefrontal cortex (DLPFC)
Number of subjects: 61

Group type: EXPERIMENTAL
Intervention: High frequency (HF) rTMS to the left pre-supplementary motor area (preSMA)
Number of subjects: 61

Group type: COMPARATOR
Intervention: Control rTMS to the vertex
Number of subjects: 61
Study: 37961683

Group type: EXPERIMENTAL
Intervention: Diffuse reflectance spectroscopy prior to PDT
Number of subjects: 13

Group type: COMPARATOR
Intervention: Laser power delivered clinically with assumed optical properties
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Laser power delivered clinically with measured optical properties
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Patient-specific treatment planning using measured optical properties
Number of subjects: 13
Study: 37961906

Group type: EXPERIMENTAL
Intervention: Mavacamten
Number of subjects: 102

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 102
Study: 37962072

Group type: EXPERIMENTAL
Intervention: Nivolumab at 3 mg/kg every 2 weeks
Number of subjects: 36
Study: 37962077

Group type: EXPERIMENTAL
Intervention: Elafibranor (80 mg once daily)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 161
Study: 37962093

Group type: EXPERIMENTAL
Intervention: Falls (more than one fall in the past 6 months)
Number of subjects: 497

Group type: COMPARATOR
Intervention: No falls
Number of subjects: 497
Study: 37962117

Group type: EXPERIMENTAL
Intervention: Intraoperative antegrade transcystic balloon sphincteroplasty
Number of subjects: 57
Study: 37962169

Group type: EXPERIMENTAL
Intervention: 18 F-FAPI PET/CT
Number of subjects: 1

Group type: COMPARATOR
Intervention: 18 F-FDG PET/CT
Number of subjects: 1
Study: 37962171

Group type: EXPERIMENTAL
Intervention: CCFES
Number of subjects: 52

Group type: EXPERIMENTAL
Intervention: CCFES + HTVG
Number of subjects: 52
Study: 37962202

Group type: EXPERIMENTAL
Intervention: Thoracic epidural analgesia (TE Group)
Number of subjects: 161

Group type: COMPARATOR
Intervention: Oral morphine (OM Group)
Number of subjects: 161
Study: 37962323

Group type: EXPERIMENTAL
Intervention: Women Farmer Stress Inventory (WFSI)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Satisfaction with Life Scale (SWLS)
Number of subjects: 592

Group type: EXPERIMENTAL
Intervention: Sociodemographic and farm-level characteristics
Number of subjects: 592
Study: 37962746

Group type: EXPERIMENTAL
Intervention: bardoxolone methyl 5-15 mg/day (titrated as tolerated)
Number of subjects: 104

Group type: COMPARATOR
Intervention: placebo
Number of subjects: 104
Study: 37962748

Group type: EXPERIMENTAL
Intervention: Early mobilisation (EM) within 72 hours of ICU admission
Number of subjects: 4190
Study: 37962771

Group type: EXPERIMENTAL
Intervention: Theta-frequency ELF-EMF (5 Hz)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Gamma-frequency ELF-EMF (40 Hz)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Combination frequency ELF-EMF (5-16-40 Hz)
Number of subjects: 0
Study: 37962876

Group type: EXPERIMENTAL
Intervention: Chloramine (Perisolv®) applied initially and after sub-gingival instrumentation in pathological pockets
Number of subjects: 38

Group type: COMPARATOR
Intervention: Non-surgical periodontal therapy
Number of subjects: 38

Group type: COMPARATOR
Intervention: Oral health-related quality of life measured with the Oral Health Impact Profile (OHIP) instrument
Number of subjects: 38
Study: 37962891

Group type: EXPERIMENTAL
Intervention: Acupuncture
Number of subjects: 298

Group type: EXPERIMENTAL
Intervention: Massage
Number of subjects: 298

Group type: COMPARATOR
Intervention: Acupuncture and Massage
Number of subjects: 298
Study: 37962917

Group type: EXPERIMENTAL
Intervention: Nationwide multi-operator self-exclusion service (Spelpaus) for gambling, involving both land- and web-based gambling sites.
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Qualitative interview study to analyze user perspectives on the self-exclusion service.
Number of subjects: 0
Study: 37962931

Group type: EXPERIMENTAL
Intervention: Wearable biosensor (Wrist Angel) used for up to 8 weeks in everyday life, with participants pressing an event tag button when experiencing distress related to OCD symptoms or fear.
Number of subjects: 18

Group type: EXPERIMENTAL
Intervention: Controlled conditions of rest and stress in the clinic before and after the 8-week observation period.
Number of subjects: 18

Group type: COMPARATOR
Intervention: Participants without a psychiatric diagnosis pressing the event tag button when feeling scared.
Number of subjects: 18
Study: 37963059

Group type: EXPERIMENTAL
Intervention: Occupational exposure to crystalline silica (assessed by job-exposure matrices)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Occupational exposure to pesticides (assessed by job-exposure matrices)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Occupational exposure to chlorinated solvents (assessed by job-exposure matrices)
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Occupational exposure to trichloroethylene (assessed by job-exposure matrices)
Number of subjects: 0

Group type: COMPARATOR
Intervention: Crystalline silica occupational exposure
Number of subjects: 0

Group type: COMPARATOR
Intervention: Chlorinated solvent occupational exposure
Number of subjects: 0
Study: 37963101

Group type: COMPARATOR
Intervention: Self-management programmes (SMP)
Number of subjects: 8249

Group type: COMPARATOR
Intervention: Health literacy skills building courses (HLSBC)
Number of subjects: 8249

Group type: COMPARATOR
Intervention: Audio-/visual education without personal feedback (AVE)
Number of subjects: 8249

Group type: COMPARATOR
Intervention: Adapted medical instruction
Number of subjects: 8249
Study: 37963155

Group type: EXPERIMENTAL
Intervention: HemoCue 301 with a cut-off of 11.1 g/dL
Number of subjects: 306

Group type: COMPARATOR
Intervention: Automated Hb with a cut-off of 10.8 g/dL
Number of subjects: 306
Study: 37963297

Group type: EXPERIMENTAL
Intervention: Respiratory viral infections
Number of subjects: 0

Group type: COMPARATOR
Intervention: Control group not specified
Number of subjects: 0
Study: 37963304

Group type: EXPERIMENTAL
Intervention: Olaparib
Number of subjects: 0
Study: 37963317

Group type: EXPERIMENTAL
Intervention: FLOT + Atezolizumab (ATZ)
Number of subjects: 295

Group type: COMPARATOR
Intervention: FLOT alone
Number of subjects: 295
Study: 37963385

Group type: EXPERIMENTAL
Intervention: Home catheter removal
Number of subjects: 117

Group type: COMPARATOR
Intervention: Office catheter removal
Number of subjects: 117
Study: 37963688

Group type: EXPERIMENTAL
Intervention: Shared decision-making and patient decision aid in consultations
Number of subjects: 0

Group type: EXPERIMENTAL
Intervention: Questionnaire feedback from patients
Number of subjects: 0
Study: 37963723

Group type: EXPERIMENTAL
Intervention: Personalised EID with a target drug trough concentration of 10 µg/mL (EID10)
Number of subjects: 376

Group type: EXPERIMENTAL
Intervention: Personalised EID with a target drug trough concentration of 5 µg/mL (EID5)
Number of subjects: 376

Group type: COMPARATOR
Intervention: Standard interval dosing (SID) of 4 weeks
Number of subjects: 376
Study: 37963771

Group type: EXPERIMENTAL
Intervention: menthol roll-your-own cigarette (mRYO)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: non-menthol cigarette (NMC)
Number of subjects: 80

Group type: EXPERIMENTAL
Intervention: menthol filtered little cigar (mFLC)
Number of subjects: 80

Group type: COMPARATOR
Intervention: usual brand menthol cigarettes (UBMC)
Number of subjects: 80
Study: 37964083

Group type: EXPERIMENTAL
Intervention: Experimental arm (human milk fortification)
Number of subjects: 82

Group type: COMPARATOR
Intervention: Control arm
Number of subjects: 82

Group type: EXPERIMENTAL
Intervention: Experimental arm
Number of subjects: 82
Study: 37964096

Group type: EXPERIMENTAL
Intervention: Oral Health Assessment Tool (OHAT)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Functional Oral Intake Scale (FOIS)
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Eating Assessment Tool (EAT)-10
Number of subjects: 39

Group type: EXPERIMENTAL
Intervention: Mini Nutritional Assessment-Short Form (MNA-SF)
Number of subjects: 39
Study: 37964187

Group type: EXPERIMENTAL
Intervention: Therapeutic ultrasound
Number of subjects: 37

Group type: COMPARATOR
Intervention: Sham group
Number of subjects: 37

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 37
Study: 37964214

Group type: EXPERIMENTAL
Intervention: Personalized surveillance (PSP)
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Personalized aftercare plans (PAP)
Number of subjects: 1040

Group type: EXPERIMENTAL
Intervention: Personalized surveillance (PSP) and personalized aftercare plans (PAP)
Number of subjects: 1040
Study: 37964221

Group type: EXPERIMENTAL
Intervention: Empagliflozin 10 mg daily
Number of subjects: 97

Group type: COMPARATOR
Intervention: Placebo
Number of subjects: 97
Study: 37964232

Group type: EXPERIMENTAL
Intervention: iCPR-guided RN care
Number of subjects: 0
Study: 37964240

Group type: EXPERIMENTAL
Intervention: Motivational Interviewing (MI) added to usual case management (UC)
Number of subjects: 514

Group type: EXPERIMENTAL
Intervention: Stratified Vocational Advice Intervention (SVAI) added to usual case management (UC)
Number of subjects: 514

Group type: COMPARATOR
Intervention: Usual Case Management (UC)
Number of subjects: 514
Study: 37964252

Group type: EXPERIMENTAL
Intervention: BodyKind programme (four lesson, school-based, teacher led, universal body image programme)
Number of subjects: 600

Group type: EXPERIMENTAL
Intervention: BodyKind programme
Number of subjects: 600
Study: 37964259

Group type: EXPERIMENTAL
Intervention: COVID-19 survivors
Number of subjects: 108
Study: 37964300

Group type: EXPERIMENTAL
Intervention: Virtual Reality exposure scenarios (neutral, living room, bar)
Number of subjects: 60
Study: 37964330

Group type: EXPERIMENTAL
Intervention: Evidence-based diabetes management package (DMP) including access to an app, health coaching, pedometer, glucometer, weighing scale, with or without M-POWER rewards scheme
Number of subjects: 0

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 0
Study: 37964367

Group type: EXPERIMENTAL
Intervention: Standardized TEACH-PD training curriculum
Number of subjects: 42

Group type: COMPARATOR
Intervention: Usual training practice
Number of subjects: 42
Study: 37964379

Group type: EXPERIMENTAL
Intervention: Cabiralizumab (anti-CSF1R), sotigalimab (CD40-agonist), and nivolumab (anti-PD-1)
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Higher doses of anti-CSF1R in murine models
Number of subjects: 13

Group type: EXPERIMENTAL
Intervention: Patients with prolonged stable disease or partial response
Number of subjects: 13
Study: 37964431

Group type: EXPERIMENTAL
Intervention: 3-mg nicotine concentration ONP
Number of subjects: 30

Group type: EXPERIMENTAL
Intervention: 6-mg nicotine concentration ONP
Number of subjects: 30

Group type: COMPARATOR
Intervention: usual brand cigarette
Number of subjects: 30
Study: 37964515

Group type: EXPERIMENTAL
Intervention: Median approach to SESPB
Number of subjects: 4

Group type: EXPERIMENTAL
Intervention: Intermediate approach to SESPB
Number of subjects: 4
Study: 37964784

Group type: EXPERIMENTAL
Intervention: ACT intervention (multidisciplinary approach including predischarge education and coordinated postdischarge follow-up)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: Education group (part of ACT intervention)
Number of subjects: 46

Group type: COMPARATOR
Intervention: Usual Care group (control)
Number of subjects: 46

Group type: EXPERIMENTAL
Intervention: ACT group (part of ACT intervention)
Number of subjects: 46
Study: 37965170

Group type: EXPERIMENTAL
Intervention: Lasmiditan
Number of subjects: 6004
Study: 37965169

Group type: EXPERIMENTAL
Intervention: Psychological-behavioral intervention (CoRE) consisting of six individual and two group sessions led by a certified psychologist.
Number of subjects: 0

Group type: COMPARATOR
Intervention: Waitlist control group (not receiving the intervention).
Number of subjects: 0
Study: 37965250

Group type: EXPERIMENTAL
Intervention: Listening to the Holy Quran recital for 10 minutes twice daily
Number of subjects: 132

Group type: COMPARATOR
Intervention: Usual care
Number of subjects: 132